NasdaqGS:XERSPharmaceuticals
Xeris Biopharma (XERS): Valuation Insights After New Recorlev Patent, Profit Boost, and 2025 Outlook Upgrade
Xeris Biopharma Holdings (XERS) just reported an impressive quarter, swinging to a profit alongside strong revenue growth and raising its outlook for 2025. The company also secured a new patent for its Recorlev treatment, which extends protection against future generics.
See our latest analysis for Xeris Biopharma Holdings.
After a stellar year, Xeris Biopharma’s recent quarter added to the momentum, as improving fundamentals and a new patent gave investors plenty to cheer about. Despite last...